Skip to main content

Table 2 Sub-group meta-analysis of the HBV–HIV co-infection pooled prevalence estimation among ANC attendees

From: Sero-prevalence of human immunodeficiency virus–hepatitis B virus (HIV–HBV) co-infection among pregnant women attending antenatal care (ANC) in sub-Saharan Africa (SSA) and the associated risk factors: a systematic review and meta-analysis

Variable Analysis
number Prevalence % (95% CI) P value I2 (%) (95% CI) P het
Region
 West Africa 16 5.16 (2.67 to 8.39) REF   92.25 (97.82 to 98.6) P < 0.0001
 East Africa 13 2.168 (0.830 to 4.116)  < 0.001* 96.79(95.68 to 97.62) P < 0.0001
 South Africa 2 2.317 (1.105 to 3.959)  < 0.001* 78.4(6.03 to 95.03) P = 0.0314
 Central Africa 7 2.441 (1.492 to 3.617)  < 0.001* 88.02(77.70 to 93.57) P < 0.0001
Year of publication
 2004–2010 8 6.356 (3.611 to 9.811)   91.15(84.97 to 94.79) P < 0.0001
 2011–2019 30 2.252 (1.452 to 3.221)  < 0.001* 97.15(96.56 to 97.64) P < 0.0001
HIV + Cohort
 Yes 12 8.312 (5.806 to 11.22)   94.90(92.69 to 96.45) P < 0.0001
 No 27 2.152 (1.358 to 3.125)  < 0.001* 96.73(95.98 to 97.33) P < 0.0001
Detection method
 ELISA 19 3.39 (2.06 to 5.047) REF   93.80(91.64 to 95.41) P < 0.0001
 RDT 13 3.167 (1.484 to 5.449) 0.2996 98.01(97.44 to 98.46) P < 0.0001
 Others 6 3.323 (0.955 to 7.050) 0.7443 98.89(98.46 to 99.20) P < 0.0001
  1. *P value is statistically significant, HIV = Human Immunodeficiency Virus, ELISA = Enzyme Linked Immuno Assay, RDT = Rapid Diagnostic Test